Compass Pathways, a mental health care company, has appointed Michael Falvey as Chief Financial Officer, replacing Piers Morgan when he leaves the company, as previously announced, at the end of the year.
Falvey is experienced in financial and operational roles in public and private growth companies. He joins Compass most recently from Karyopharm Therapeutics, where he led financial strategy and prepared the financial infrastructure to support commercial operations as the company delivered pivotal clinical data and prepared to commercialise its first product.
Prior to Karyopharm Therapeutics, Mr Falvey served as CFO at several other companies including Seven Bridges Genomics, Analysis Group, Ahura Scientific, and Aspect Medical Systems, and as VP, Finance, at Millennium Pharmaceuticals. He holds a Master of Science in Management from the Sloan School of Management at the Massachusetts Institute of Technology and a Bachelor of Science from Georgetown University.
Falvey said: “This is an exciting time to be joining Compass Pathways, following the publication of its positive Phase IIb topline data earlier this month. They have already achieved so much – raising more than $425 million, completing the world’s largest, randomised, controlled psilocybin therapy clinical trial, creating new approaches in mental health care for treatment-resistant depression and now PTSD – and I look forward to being part of the team and contributing to its success.”
George Goldsmith, CEO and Co-founder, Compass Pathways, said: “Mike has an excellent reputation for executing business growth plans and a track record in building strong financial teams. He also has experience of launching and commercialising products which will be invaluable as we bring our COMP360 psilocybin therapy through clinical trials and develop our plans for bringing it to patients. We are so pleased to welcome him to our team and look forward to working together to transform mental health care.”
